Accordingly, restoration of p53 activity through the use of small-molecule inhibitors targeting the hydrophobic protein–protein interaction site between MDM2 and p53 has become a feasible targeted therapeutic strategy for various cancers (62, 63). Here, MDM2 is linked to cancer.